Skip to contentA
Aclaris Therapeutics, Inc.
A
ACRSAclaris Therapeutics, Inc. Q3 2017 · 10-Q
Revenue$684.00K$684.00Kno prior Q3 2016 on file Net Income-$18.19M-$18.19MN/M vs Q3 2016 EPS Diluted-$0.63-$0.63N/M vs Q3 2016 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
Operating Cash Flowderived-$13,714,000N/M Free Cash Flowderived-$13,984,000N/M Margins · derivedGross margin33.8%
Operating margin-2742.1%
Net margin-2659.6%
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end